LYFE Capital

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

CytoTronics is focused on designing and developing advanced cell culture plates that incorporate embedded high-density electronic systems. This innovative technology enables researchers to visualize live cell functions on a large scale and obtain real-time data on cell behavior. By facilitating detailed studies of complex biological processes, CytoTronics aims to support significant advancements in fields such as drug discovery and personalized medicine. The company's semiconductor-based systems provide a valuable tool for researchers, enhancing their ability to investigate cellular dynamics and improve the understanding of cellular interactions.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.

Elite Technology is a company that specializes in the development of chromatographic techniques, workstations, and high-performance liquid chromatography equipment for analysis, preparation, and industrial production.

HC Scientific (Chengdu) L.L.C., established in 2016, is a national high-tech enterprise focused on developing intelligent solutions in life technology. The company aims to empower life sciences through innovative products, including genetic testing instruments, reagents, and software, primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is committed to autonomous research and development of intellectual property and is recognized for its contributions to China's new economy development initiatives. The organization employs a team of experts, including returning PhDs and professors, who have developed advanced life science technology platforms. Through its diverse product pipeline, HC Scientific streamlines complex tasks for practitioners in the life science field, thereby creating substantial value for its partners and contributing to significant national and provincial scientific and technological projects.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Noah Medical is a manufacturer of medical robotic devices specialized in the diagnosis and treatment of patients across various medical conditions. The company's innovative devices facilitate early diagnoses and treatments within advanced clinical environments, empowering hospitals to address health issues promptly. This capability not only enhances patient outcomes but also contributes to reduced scarring, thereby improving the overall quality of care.

Genepoint Biological Technology, based in Shanghai, China, specializes in manufacturing and distributing advanced devices for cryogenic biomaterial storage and handling. Their product portfolio includes automated cryo-bio storage systems, hybrid cryo-storage solutions, LIN vapor freezers, and specialized hoists for freezers, catering to life sciences researchers. The company is committed to advancing IoT, automation, and intelligence technologies in the field of cryogenic biomaterial management.

Dieshi-DISC is a soft hydrophilic contact lens that was developed and marketed. Their new type of hydrophilic contact lens can delay the progression of myopia. After wearing the lens, the retina will produce a clear image, and there will be out-of-focus or blurred images in front of the patient.

iECURE is a gene editing company developing mutation-agnostic in vivo gene insertion therapies to treat rare, life-threatening liver disorders in children. Its approach seeks long-term, potentially curative treatment for metabolic liver diseases caused by loss-of-function mutations, with initial programs targeting ornithine transcarbamylase deficiency, citrullinemia type 1, and phenylketonuria.

Edgene Biot is a life sciences company focused on advancing biotechnology through innovative genetic engineering techniques. It specializes in digital precision breeding technology and offers a range of platforms, including gene editing, molecular biology, and high-throughput genetic transformation, alongside a gene bank and a detection and analysis platform. These resources enable clients to enhance environmental control throughout the cultivation process of genetically transformed crops. Edgene Biot aims to lead the market in the application of digital biotechnology in biological breeding by scaling production and accelerating the transformation of achievements, informed by a comprehensive understanding of both domestic and international biotechnology trends and the growth of the biological breeding industry.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and drug discovery. Founded in 2010, the company focuses on the development of ion channel-related drugs, particularly targeting the nervous and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel screening, cardiac safety panels, and molecular biology, utilizing proprietary cell lines for voltage-gated and ligand-gated ion channels. The company is also dedicated to expanding its capabilities in immunology, oncology, and other areas, providing comprehensive support for target validation and preclinical candidate identification. Through its advanced screening platforms and flexible collaboration models, ICE Bioscience aims to enhance the efficiency of the drug discovery process for various clinical needs.

Biointron, founded in 2012 and based in Shanghai, China, specializes in the development of recombinant antibody technology and offers comprehensive contract research organization (CRO) services. The company aims to expedite the antibody discovery process by providing a one-stop solution for antibody development. Biointron utilizes advanced technologies, including rapid expression platforms, antibody sequencing, and labeling tools, to achieve high-throughput recombinant antibody production. Its commitment to delivering high-quality and cost-effective recombinant protein and antibody reagents positions Biointron as a significant player in the biotechnology sector, catering to the needs of researchers and organizations in the field.

Baiying Bio offers economic recombinant protein and antibody reagents and is a CRO vendor for life science researchers and biopharma companies. They provide services including HTP recombinant antibody and VHH production, bispecific antibody production, antibody humanization, VHH library generation, hybridoma sequencing, protein expression in mammalian cells, large-scale antibody production, and more. They delivered tens of thousands of recombinant antibodies to customers.

MobiDrop Biotech specializes in developing microfluidic technologies tailored for life sciences and precision medicine. The company is dedicated to enhancing molecular diagnostics and life science research through innovative platforms that improve the accuracy and efficiency of diagnosis and testing. MobiDrop produces integrated machine platforms, microfluidic detection chips, extensive assays, and user-friendly software specifically designed for digital droplet PCR and single-cell multi-omic applications. Its products find applications in molecular diagnostics, cancer screening, and drug research and development, providing groundbreaking solutions that advance the quality of healthcare and research capabilities.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

Starna Therapeutics is a biotechnology company dedicated to the development of innovative drugs centered around RNA technology. The company boasts an advanced RNA and organ-selective delivery platform, supported by independent intellectual property rights. Starna Therapeutics focuses on addressing unmet clinical needs through its extensive research and development pipeline, which encompasses a range of therapeutic areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its expertise in RNA technology, Starna Therapeutics aims to create effective solutions for various health challenges.

Boyue Bio focuses on the development of biomedical raw materials and integrated solutions. The company's four product lines include Bioactive Materials, Nanometer Microspheres, Chromatographic Products, and Integrated Solutions. Boyue Bio seeks to be a major provider of total solutions and core raw materials for the biomedical industry.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

SUSTAO is a manufacturer of consumables that meet the technical requirements of medical robots.

Elixir Clinical Research is a technology-driven company that specializes in providing comprehensive clinical research services. The firm focuses on various aspects of clinical trials, including bioequivalence studies (BE) and Phase I-IV clinical trials, as well as real-world research and final application registration. Additionally, Elixir offers services in clinical research program design, medical strategy, regulatory registration, center management, data management, biostatistics, and real-world research. These services are designed to help pharmaceutical companies efficiently launch new drugs by providing qualified and effective clinical research solutions.

Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.

Levostar Biotechnology is a biotechnology company focused on the development and manufacture of cell and gene therapy products. It offers comprehensive solutions for the cell and gene therapy industry, including clinical testing services for various therapy platforms, viral vector platforms, mRNA vaccines, and therapeutic platforms. The company emphasizes GMP-level production processes and stringent quality control methods for plasmids and mRNAs. By providing these advanced technologies and services, Levostar aims to facilitate and accelerate research and development in gene cell therapy and mRNA drug innovation.

CellOrigin Biotech is a biotechnology company dedicated to the development of immune cell therapies utilizing induced pluripotent stem cells (iPSCs). The company specializes in creating iPSC-derived innate immune cells aimed at treating solid tumors. Its focus encompasses the research and development of innovative technologies, including gene-manipulated clinical iPSCs and an efficient platform for iPSC differentiation. Additionally, CellOrigin Biotech operates a clinical iPSC bank, which supports its goal of advancing therapeutic solutions through mature stem cell reprogramming techniques.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

Genepoint Biological Technology, based in Shanghai, China, specializes in manufacturing and distributing advanced devices for cryogenic biomaterial storage and handling. Their product portfolio includes automated cryo-bio storage systems, hybrid cryo-storage solutions, LIN vapor freezers, and specialized hoists for freezers, catering to life sciences researchers. The company is committed to advancing IoT, automation, and intelligence technologies in the field of cryogenic biomaterial management.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Hugo Biotech is a developer of high-throughput microbial sequencing technology, specializing in the analysis of microbial genomes and associated big data. The company has sequenced nearly 20,000 clinical samples for over 300 leading hospitals in China. Its innovative approach allows for the rapid and precise detection of pathogenic microorganisms in clinical samples, bypassing traditional culturing processes and specific amplification methods. This technology enhances the efficiency of microbial identification in healthcare settings, contributing to improved patient outcomes through timely diagnosis and treatment.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.

Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company that focuses on the development and commercialization of protein and peptide-based drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company targets multiple therapeutic areas, including diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neurodegenerative disorders. Sciwind's innovative drug candidates are particularly designed to address metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for physicians and their patients.

MingMed is a Chinese pharmaceutical company focused on independent drug research and development, demonstrating strong global competitiveness. The company specializes in a diverse product pipeline that includes ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs, and immune therapies for pets. MingMed also emphasizes innovation, with several potential First-in-Class drugs currently in the clinical stage. Its research spans various therapeutic areas, delivering cutting-edge solutions in ophthalmology, medical aesthetics, and veterinary medicine, particularly through small molecule immune drugs and gene editing-based cell therapies.

HC Scientific (Chengdu) L.L.C., established in 2016, is a national high-tech enterprise focused on developing intelligent solutions in life technology. The company aims to empower life sciences through innovative products, including genetic testing instruments, reagents, and software, primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is committed to autonomous research and development of intellectual property and is recognized for its contributions to China's new economy development initiatives. The organization employs a team of experts, including returning PhDs and professors, who have developed advanced life science technology platforms. Through its diverse product pipeline, HC Scientific streamlines complex tasks for practitioners in the life science field, thereby creating substantial value for its partners and contributing to significant national and provincial scientific and technological projects.

Hugo Biotech is a developer of high-throughput microbial sequencing technology, specializing in the analysis of microbial genomes and associated big data. The company has sequenced nearly 20,000 clinical samples for over 300 leading hospitals in China. Its innovative approach allows for the rapid and precise detection of pathogenic microorganisms in clinical samples, bypassing traditional culturing processes and specific amplification methods. This technology enhances the efficiency of microbial identification in healthcare settings, contributing to improved patient outcomes through timely diagnosis and treatment.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

General Biosystems is a biotechnology company that focuses on high-quality, high-throughput, automated production of DNA constructs. The company through its passion in understanding how genetic information is stored and programmed in the DNA develops innovative technologies and instruments to program and physically write or print new genetic codes. The new codes will create blueprints for new or enhanced biological and biological functions.

Zhenyi Yiliao is a medical enterprise focusing on structural heart disease.

Just Medical is a developer and manufacturer of artificial orthopedic implant devices and systems, specializing in products such as artificial hip and knee joints, internal fixation products, and orthopedic surgical instruments. The company is dedicated to enhancing surgical efficiency and improving the quality of orthopedic treatment through advanced technology research and development. Just Medical focuses on creating safe and effective medical products and services, continually refining its product system to address the needs of healthcare providers and alleviate patient pain. Its commitment to high-speed development and excellence positions it as a key player in the orthopedic medical device industry.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

ImmuneOnco Biopharma, founded in June 2015 in Zhangjiang High-Tech Park, Shanghai, is an innovative biopharmaceutical company focused on developing and commercializing novel cancer immunotherapy products. The company aims to reverse immune inhibition caused by cancer cells and actively eliminate these cells. ImmuneOnco is recognized for its systematic approach to leveraging both innate and adaptive immune systems in its research and development efforts. The company boasts a robust pipeline of 14 drug candidates, with eight currently undergoing clinical programs, highlighting its commitment to advancing immuno-oncology therapies. ImmuneOnco's extensive understanding of cancer biology and immunology enables it to transform scientific research into viable therapeutic options.

ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, founded in 2016. The company specializes in offering a variety of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and western blot tools and reagents. In addition to its extensive product range, ABclonal provides customized services related to peptides, antibodies, and proteins. The company distributes its products through a network of distributors across Europe, Asia, North America, and Oceania, aiming to enhance the quality of life science research with its high-quality offerings.

Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company that focuses on the development and commercialization of protein and peptide-based drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company targets multiple therapeutic areas, including diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neurodegenerative disorders. Sciwind's innovative drug candidates are particularly designed to address metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for physicians and their patients.

Cleveland Diagnostics is a commercial-stage company based in Cleveland, Ohio, focused on developing and commercializing innovative cancer diagnostic tests. Founded in 2013, the company specializes in creating non-invasive screening tools for various cancers, including prostate, breast, ovarian, lung, and certain neurological diseases. Their portfolio includes blood-based tests designed to enhance early detection and improve patient outcomes. Cleveland Diagnostics employs a proprietary solvent interaction analysis technology that examines protein biomarkers at a structural level, offering more precise insights into disease processes and enhancing test specificity. The company has established strategic collaborations with industry partners, such as Genomic Health, to advance its diagnostic capabilities.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.

ImmuneOnco Biopharma, founded in June 2015 in Zhangjiang High-Tech Park, Shanghai, is an innovative biopharmaceutical company focused on developing and commercializing novel cancer immunotherapy products. The company aims to reverse immune inhibition caused by cancer cells and actively eliminate these cells. ImmuneOnco is recognized for its systematic approach to leveraging both innate and adaptive immune systems in its research and development efforts. The company boasts a robust pipeline of 14 drug candidates, with eight currently undergoing clinical programs, highlighting its commitment to advancing immuno-oncology therapies. ImmuneOnco's extensive understanding of cancer biology and immunology enables it to transform scientific research into viable therapeutic options.

Shenqi Medical specializes in the research and manufacturing of innovative medical devices, primarily targeting the Chinese market. The company offers a diverse product portfolio that includes solutions for cardiovascular issues, structural heart diseases, and both peripheral and neurovascular medical devices. Additionally, Shenqi Medical is dedicated to developing minimally invasive surgical products, which enhance the safety and reliability of cardiovascular surgeries. Through its focus on advanced medical technology, Shenqi Medical aims to improve patient outcomes and contribute to the evolving landscape of healthcare.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Just Medical is a developer and manufacturer of artificial orthopedic implant devices and systems, specializing in products such as artificial hip and knee joints, internal fixation products, and orthopedic surgical instruments. The company is dedicated to enhancing surgical efficiency and improving the quality of orthopedic treatment through advanced technology research and development. Just Medical focuses on creating safe and effective medical products and services, continually refining its product system to address the needs of healthcare providers and alleviate patient pain. Its commitment to high-speed development and excellence positions it as a key player in the orthopedic medical device industry.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Aohua is a global provider of endoscopy devices and solutions, focused on advancing endoscope technology and enhancing diagnostic and treatment capabilities in endoscopy. Founded in 1994 and based in Shanghai, China, the company specializes in the research, development, production, and sales of electronic endoscope equipment, along with associated diagnostic and surgical consumables. Aohua aims to lead innovation in endoscopic technology, contributing to the overall progress of medical endoscopy practices.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.

Laviana Pharma Co., Ltd. founded in 2005 is a high-tech enterprise. It specializes in providing process and manufacture outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products. It also provides CMC services for IND and NDA submission of innovative developmental drug. It has three wholly-owned subsidiary, namely, Beijing laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in United States.

Baixing Pingan Yaofang is an online pharmacy. They serve vitamin C, vitamin AD, zinc, calcium, carbonate, vitamin AD, cod liver oil, calcium complex multi-vitamins, complex minerals, and kidney nourishes the kidneys and the liver, and gelatin contains folic acid.

Bondent Technology Co., Ltd., headquartered in Shanghai, China, specializes in supplying dental equipment and materials. It offers a comprehensive range of services, including technical training, operational and management consulting, decoration design, and financial solutions. Bondent's core business involves the design, development, manufacturing, and sales of oral medical equipment, creating a full ecosystem for the dental and oral health industry.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Fuzhou Kangwei Network Technology is a management platform for blood glucose disease monitoring. They offer a data engine to provide decision support for doctors' diagnoses and treatments. Their data engine recommends diagnosis and treatment suggestions based on the patient's blood glucose data, and doctors can formulate diagnosis and treatment plans professionally and quickly according to the patient's condition.

WinnTi Medical creates medical devices through continuous product innovations and manufacturing improvements, meeting surgeons' increasing demands, and improving patients' wellness.